Hoechst Marion Roussel Licenses Database from Genome Therapeutics | GenomeWeb

WALTHAM, Mass.--Genome Therapeutics here has licensed its proprietary microbial sequence database, PathoGenome, to Hoechst Marion Roussel. The pharmaceutical company will use the database to develop antiinfective products. Hoechst will pay annual subscription fees and royalties for nonexclusive access to the database. PathoGenome contains genomic sequence information from 24 microbial organisms assembled through Genome Therapeutics' pathogen genomics research and public-domain sources, as well as in-depth sequence analysis and proprietary bioinformatics tools.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.